These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 4990003)

  • 1. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice.
    Neil GL; Moxley TE; Manak RC
    Cancer Res; 1970 Aug; 30(8):2166-72. PubMed ID: 4990003
    [No Abstract]   [Full Text] [Related]  

  • 2. Antitumor effect of 1-beta-D-arabinofuranosylcytosine 5'-adamantoate (NSC 117614) in L1210 leukemic mice.
    Neil GL; Wiley PF; Manak RC; Moxley TE
    Cancer Res; 1970 Apr; 30(4):1047-54. PubMed ID: 5504347
    [No Abstract]   [Full Text] [Related]  

  • 3. Antitumor effect and mode of action of 1-beta-D-arabinofuranosylcytosine 5'-phosphate in leukemia L1210.
    Schrecker AW; Goldin A
    Cancer Res; 1968 Apr; 28(4):802-3. PubMed ID: 5649067
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia.
    Rustum YM; Dave C; Mayhew E; Papahadjopoulos D
    Cancer Res; 1979 Apr; 39(4):1390-5. PubMed ID: 421223
    [No Abstract]   [Full Text] [Related]  

  • 5. Sparing action of uridine on the activity of arabinosylcytosine with normal and leukemic mice.
    Saslaw LD; Grindey GB; Kline I; Waravdekar VS
    Cancer Res; 1968 Jan; 28(1):11-20. PubMed ID: 5635365
    [No Abstract]   [Full Text] [Related]  

  • 6. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
    Burns ER; Scheving LE
    Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapy of leukemia L1210 in mice with 1-beta-d-arabinofuranosylcytosine hydrochloride. I. Influence of treatment schedules.
    Kline I; Venditti JM; Tyrer DD; Goldin A
    Cancer Res; 1966 May; 26(5):853-9. PubMed ID: 5936445
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral and parenteral activity of 2,2'-anhydro-1- -D-arabinofuranosyl-5-fluorocytosine against both intraperitoneally and intracerebrally inoculated mouse leukemia.
    Fox JJ; Falco EA; Wempen I; Pomeroy D; Dowling MD; Burchenal JH
    Cancer Res; 1972 Oct; 32(10):2269-72. PubMed ID: 4673145
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of 4,4'-diacetyl-diphenyl-urea-bis(guanylhydrazone) on leukemia L1210.
    Mihich E; Mulhern AI
    Cancer Res; 1968 Feb; 28(2):354-62. PubMed ID: 5641525
    [No Abstract]   [Full Text] [Related]  

  • 10. A microbiological assay for cyclocytidine--disposition studies in mice.
    Neil GL; Kuentzel SL; Berger AE
    Res Commun Chem Pathol Pharmacol; 1973 May; 5(3):561-72. PubMed ID: 4633769
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemotherapy of leukemia L1210 in mice with 1-beta-D-arabinofuranosylcytosine hydrochloride. II. Effectiveness against intracerebrally and subcutaneously inoculated leukemic cells.
    Kline I; Venditti JM; Tyrer DD; Mantel N; Goldin A
    Cancer Res; 1966 Sep; 26(9):1930-7. PubMed ID: 5924958
    [No Abstract]   [Full Text] [Related]  

  • 12. Metabolism of 1-beta-D-arabinofuranosylcytosine in leukemia L1210: studies with intact cells.
    Shrecker AW; Urshel MJ
    Cancer Res; 1968 Apr; 28(4):793-801. PubMed ID: 5649066
    [No Abstract]   [Full Text] [Related]  

  • 13. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin.
    Edelstein M; Vietti T; Valeriote F
    Cancer Res; 1974 Feb; 34(2):293-7. PubMed ID: 4810905
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined chronochemotherapy of L1210 leukemic mice using 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine, methylprednisolone and cis-diamminedichloroplatinum.
    Scheving LE; Burns ER; Halberg F; Pauly JE
    Chronobiologia; 1980; 7(1):33-40. PubMed ID: 7192203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the mode of action of 2,2'-anhydro-1- -D-arabinofuranosylcytosine.
    Wang MC; Sharma RA; Bloch A
    Cancer Res; 1973 Jun; 33(6):1265-71. PubMed ID: 4578070
    [No Abstract]   [Full Text] [Related]  

  • 16. Biochemical and pharmacologic studies with 1- -D-arabinofuranosylcytosine 5'-adamantoate (NSC-117614), a depot form of cytarabine.
    Neil GL; Buskirk HH; Moxley TE; Manak RC; Kuentzel SL; Bhuyan BK
    Biochem Pharmacol; 1971 Dec; 20(12):3295-308. PubMed ID: 5002403
    [No Abstract]   [Full Text] [Related]  

  • 17. Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice.
    Neil GL; Moxley TE; Kuentzel SL; Manak RC; Hanka LJ
    Cancer Chemother Rep; 1975; 59(3):459-65. PubMed ID: 54211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity studies in vivo of liposomal phospholipid-N4-palmitoyl- and N4-hexadecyl-1-beta-D-arabinofuranosylcytosine conjugates.
    Schott H; Schwendener RA
    Anticancer Drug Des; 1996 Sep; 11(6):451-62. PubMed ID: 8836110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 2'-deoxycoformycin, 9-beta-D-arabinofuranosyladenine 5'-phosphate, and 1-beta-D-arabinofuranosylcytosine triple combination therapy on intracerebral leukemia 1210.
    Caron N; Lee SH; Kimball AP
    Cancer Res; 1977 Sep; 37(9):3274-9. PubMed ID: 884674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic considerations in evaluating the effects of tetrahydrouridine on 5-azacytidine chemotherapy in L1210 leukemic mice.
    Kelly CJ; Gaudio L; Yesair DW; Schoenemann PT; Wodinsky I
    Cancer Treat Rep; 1978 Jul; 62(7):1025-32. PubMed ID: 80268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.